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The B cell survival factor (TNFSF13B/BAFF) is often elevated in autoimmune diseases and is
targeted in the clinic for the treatment of systemic lupus erythematosus. BAFF contains a
loop region designated the ﬂap, which is dispensable for receptor binding. Here we show that
the ﬂap of BAFF has two functions. In addition to facilitating the formation of a highly active
BAFF 60-mer as shown previously, it also converts binding of BAFF to TNFRSF13C (BAFFR)
into a signaling event via oligomerization of individual BAFF-BAFFR complexes. Binding and
activation of BAFFR can therefore be targeted independently to inhibit or activate the function
of BAFF. Moreover, structural analyses suggest that the ﬂap of BAFF 60-mer temporarily
prevents binding of an anti-BAFF antibody (belimumab) but not of a decoy receptor (ataci-
cept). The observed differences in proﬁles of BAFF inhibition may confer distinct biological
and clinical efﬁcacies to these therapeutically relevant inhibitors.
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B cells actively participate in the adaptive immune response.Their main function is to produce antibodies that protectagainst bacterial infections. Antibodies are respectively
absent or low in patients with X-linked agammaglobulinemia, who
selectively lack B but not T cells, and in patients with common
variable immunodeﬁciency. In both cases, infections of the
respiratory and gastro-intestinal tracts are the most common
symptoms that can be largely prevented by transfer of immu-
noglobulins1,2. Systemic lupus erythematosus (SLE), on the con-
trary, is characterized by excessive B cell activity and production of
autoantibodies that form autoimmune complexes, trigger com-
plement activation, and deposit in glomeruli which can cause
nephropathies3. The B cell activation factor of the tumor necrosis
factor (TNF) family (BAFF, also known as TNFSF13B or B lym-
phocyte stimulator, BLyS) is often elevated in SLE (reviewed in
refs. 4,5). An anti-BAFF therapy (belimumab, trade name Ben-
lysta) was approved in 2011 for the treatment of adult patients
with active, autoantibody-positive SLE. Other BAFF inhibitors are
in clinical development, some of which, like a TACI (transmem-
brane activator and calcium modulator and cyclophilin ligand
interactor, TNFRSF13B)-Fc decoy receptor (atacicept), addition-
ally inhibit a proliferation-inducing ligand (APRIL, also known as
TNFSF13) (reviewed in refs. 4,5). BAFF and APRIL are important
ﬁtness and survival factors for mature B cells and plasma cells6.
They are homo-trimeric type-II transmembrane proteins that can
be proteolytically processed at furin consensus cleavage sites to
release soluble cytokines7–9. BAFF is expressed by cells of myeloid
origin and by stromal cells10. It binds to three receptors, BAFF
receptor (BAFFR, TNFRSF13C), TACI, and B cell maturation
antigen (BCMA, TNFRSF17), while APRIL interacts only with
TACI and BCMA (reviewed in ref. 6). While BAFFR, TACI, and
BCMA are all expressed in B cells at different stages of develop-
ment, BAFFR is the ﬁrst one to be expressed and the only one
required for survival of transitional and mature naive B cells11,12.
TACI is expressed in B cells upon activation13 and is expressed at
higher levels in marginal zone B cells14 while expression of BCMA
may require down-regulation of BAFFR15 and is found in germ-
inal center B cells16 and in terminally differentiated B cells17,18.
Soluble BAFF 3-mers can exist as such, or further assemble, at
least for human BAFF in vitro, into ordered dodecahedrons called
BAFF 60-mer19. Primary mouse B cells activated in vitro with an
anti-B cell receptor antibody can receive survival signals through
either BAFFR or TACI. In this system, BAFFR responds to all
forms of BAFF, while TACI is only activated by higher order
multimers of BAFF or APRIL20, suggesting that soluble BAFF 3-
mer provides the general survival signal for B cells, while other
forms of BAFF and APRIL, such as BAFF 60-mer, proteoglycan-
bound APRIL, or the membrane-bound ligands, would serve distinct
or additional functions. This view ﬁts with the observation that mice
expressing uncleavable BAFF display reduced levels of soluble BAFF
and a phenotype similar to that of Baff (Tnfsf13b)−/− mice21. In
order to form BAFF 60-mer, 3-mers interact with their neighbors
via a loop region of 10 amino acid residues located between β-
sheets D and E of BAFF, called as the ﬂap19. In this study, we
describe that this ﬂap is dispensable for receptor binding but
essential for the activity of soluble BAFF 3-mers acting on
BAFFR. This function of the ﬂap beyond 60-mer assembly is an
essential feature of the mechanism of action of BAFF and suggests
new strategies to either activate or inhibit BAFF activity. We also
describe that the BAFF inhibitors belimumab and atacicept differ
in their mechanism of BAFF 60-mer inhibition.
Results
Flap mutations do not affect binding of BAFF to receptors. To
address the question of how BAFF activates BAFFR, and therefore
promotes B cell survival, mutations were designed to inhibit
interactions between adjacent ﬂaps. Mutation of histidine 218
(H218A; in mouse: H242A) at the periphery of the ﬂap prevents
formation of BAFF 60-mer22. Mutation E223K (in mouse:
E247K) was also generated because glutamic acid 223 makes a
hydrogen bond with lysine 216 at the center of the ﬂap–ﬂap
interaction (Fig. 1a).
Recombinant wild type (WT) and ﬂap mutant BAFF, FLAG-
tagged or naturally cleaved, were size-fractionated to recover 3-
mers, quantiﬁed by western blot (Fig. 1b, c) and found to all bind
immobilized recombinant receptors (BAFFR, TACI, and BCMA)
similarly (Fig. 1d). This result was conﬁrmed in a competitive
enzyme-linked immunosorbent assay (ELISA) where FLAG-
tagged WT or mutant BAFF competed with naturally cleaved
untagged WT BAFF for receptor binding. Competition curves
were indistinguishable, indicating no major difference in the
binding afﬁnities of WT and mutant BAFF to BAFFR (Fig. 1e).
WT and mutant BAFF bound identically to endogenous BAFFR
on BJAB Burkitt lymphoma cells, and to TACI expressed in
BAFFR-ko BJAB cells (Supplementary Fig. 1). We conclude that
ﬂap mutations selected in this study do not affect binding of
BAFF to recombinant receptors, agreeing with crystal structures
of BAFF–BAFFR complexes in which ﬂaps make no contact with
receptors23,24.
Flap mutations prevent human BAFF to form 60-mers. Natu-
rally cleaved forms of human BAFF eluted from a size-exclusion
chromatography column as 3-mers (fractions 15–16), while
mouse BAFF formed larger complexes and eluted in fractions
13–14 (Fig. 2a, b). Only WT human BAFF also eluted as BAFF
60-mer in fractions 9–10 (Fig. 2a). All mouse BAFF constructs
produced some high-molecular-weight aggregates eluting in the
void volume of the column (fractions 7–9) (Fig. 2b), but in
contrast to human BAFF 60-mer, these aggregates were inactive
when tested for activity on reporter cells (Fig. 2a, b). Thus, as
predicted, both ﬂap mutants prevent 60-mer formation in human
BAFF. Lack of active BAFF 60-mer formation in naturally cleaved
mouse BAFF may result from an additional exon present in
mouse and rat Baff genes that introduces 30 amino acids at the N-
terminus of soluble BAFF. This N-terminal extension possibly
interferes with 60-mer assembly by steric hindrance (reviewed in
ref. 25).
Flap–ﬂap interactions are required for BAFF activity. WT
human BAFF 3-mer was active on BAFFR:TNF receptor super-
family member 6 (Fas) reporter cells (Fig. 2a). While this activity
may be due to re-association into 60-mer, this is unlikely to be the
only cause of activity since hBAFF H218A and mBAFF H242A,
which cannot form 60-mer, were also active (Fig. 2a, b). Inter-
estingly, hBAFF E223K and mBAFF E247K were inactive when
tested on BAFFR:Fas reporter cells (Fig. 2a, b), showing that the
two ﬂap mutations tested in this study are not equivalent. This
suggests that the ﬂap could serve functions different from that of
allowing 60-mer formation.
B cell lymphopenia in E247K ﬂap mutant knock-in mice. A
knock-in mouse carrying point mutation E247K in exon 6 of the
Baff gene was generated to validate the effect of BAFF ﬂap
mutation in a physiologically relevant setting (Supplementary
Fig. 2). Endogenous serum levels of circulating BAFF were similar
in littermates of Baffwt/wt (WT), Baffwt/E247K (heterozygous), and
BaffE247K/E247K (knock-in), but were at background in Baff–/–
(knock-out) mice (Fig. 3a). The same was true when receptor
binding-competent BAFF was monitored using a recombinant
receptor (TACI-Fc) and an antibody (Fig. 3b). We conclude that
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knock-in mice express and conventionally process BAFF E247K
that is then able to bind receptors. Despite the presence of cir-
culating BAFF, the B cell phenotype of knock-in mice resembled
that of BAFF knock-out with reduced numbers of CD19+CD93−
mature B cells in the spleen, decreased B/T ratio in lymph nodes,
but normal numbers of (BAFF-independent) immature CD19+
CD93+ splenic B cells (Fig. 3c–f, Supplementary Fig. 3, Supple-
mentary Table 1). There was a non-signiﬁcant trend (p > 0.05 by
one-way Anova) for slightly higher numbers of mature B cells in
knock-in mice compared to knock-out, which might reﬂect a
residual activity of either soluble or membrane-bound BAFF
E247K (Fig. 3c–f). These results indicate that BAFF E247K can-
not, or only very poorly, activate BAFFR in vivo.
In the absence of B cells, circulating levels of BAFF usually
rise20,26. We wondered why BAFF levels in B lymphopenic
knock-in mice were not higher than in WT and we found that the
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Fig. 1Mutations in the ﬂap do not affect binding of BAFF to its receptors. a Residues involved in ﬂap–ﬂap interactions between adjacent BAFF 3-mers. Parts
of BAFF monomers in adjacent 3-mers are shown in black and white, respectively. Side chains of some residues known or predicted to be important for
ﬂap–ﬂap interactions are depicted and numbered according to the human BAFF sequence. The illustration was drawn from coordinates PDB-ID 4V4623. b
FLAG-tagged human BAFF 3-mers wild type (WT) or with mutations (H218A and E223K) in ﬂap residues were produced by transient transfection of 293
T cells, recovered in supernatants, size fractionated by gel ﬁltration and adjusted to comparable concentrations. 80 ng of each protein was analyzed by
anti-FLAG western blotting. c Same as panel b, but for FLAG-tagged mouse BAFF with the corresponding ﬂap mutations. d ELISA was used to monitor the
binding of WT or mutant FLAG-tagged BAFF to recombinant BAFFR-Fc, TACI-Fc, or BCMA-Fc, with anti-FLAG detection. Binding of human BAFF was
probed on human receptors (graphs on the top), and binding of mouse BAFF on mouse receptors (graphs at the bottom). The experiment was performed
twice. e Titrated amounts of untagged WT BAFF were added to BAFFR-Fc coated in an ELISA plate, followed by a ﬁxed amount of FLAG-BAFF (WT or the
indicated mutants) and detection of binding with an anti-FLAG antibody. Absence of signal reveals that untagged BAFF had bound to BAFFR-Fc. Left graph:
human BAFF on hBAFFR-Fc. Right graph: mouse BAFF on mBAFFR-Fc. The experiment was performed once for human BAFF and twice for mouse BAFF. See
also Supplementary Fig. 1
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pair of antibodies used to monitor endogenous BAFF recognized
WT mBAFF slightly better than E247K mBAFF (Supplementary
Fig. 4). This indicates that circulating levels of mBAFF E247K
may be equal or slightly higher than in WT, although not
overwhelmingly higher.
Heterozygous (Baffwt/E247K) mice had a phenotype intermedi-
ate between WT and knock-in (Fig. 3c–f, Supplementary Table 1).
A similar intermediate phenotype was observed in BAFF+/− mice
(Fig. 3g, h, Supplementary Table 2), suggesting that gene dosage,
and not a dominant negative action of BAFF E247K, is the most
likely cause of these phenotypes.
A model for two distinct roles of the ﬂap of BAFF. Knowing
that (i) two BAFF 3-mers or more can interact via ﬂap–ﬂap
interactions19, (ii) binding to receptors does not require a func-
tional ﬂap (Fig. 1 and Supplementary Fig. 1), (iii) the ﬂap is
required for the activity of BAFF (Figs. 2 and 3), and (iv)
recombinant human BAFF is stable either as 3-mer or 60-mer,
but not as smaller intermediates such as 6-mer (Fig. 2a)19,20,22,
we propose that one BAFF 3-mer binds to three BAFFR on a B
cell to form an initial complex with no or little signaling ability
until two or more complexes are assembled via ﬂap-mediated
BAFF–BAFF interactions of BAFF 3-mers contained in these
complexes (Fig. 4a). These ﬂap–ﬂap contacts require hGlu223/
mGlu247, but not hHis218/mHis242.
Under certain conditions, BAFF–BAFF interactions may be
stabilized into even more active 60-mer by additional contacts
involving H218, at least for human BAFF (Fig. 4a)20. Residues
participating to the core ﬂap–ﬂap interaction that is essential for
BAFF activity, like Glu223, are conserved in BAFF of mammals,
birds, reptiles, ﬁshes, and sharks, while H218 that is required for
60-mer formation but is not essential for activity is usually not
conserved in batrachians and ﬁshes, and may not be relevant in
mice and rats (Figs. 2b and 4b). In contrast, the BAFF-like protein
of sea lamprey has no ﬂap (Fig. 4b)27.
If the ﬂap really serves the role of connecting BAFF 3-mers in
order to activate signaling, as proposed in the model (Fig. 4a),
cross-linking antibodies or other strategies to multimerize BAFF
should compensate for a deﬁcient ﬂap.
Cross-linking of BAFF 3-mer rescues ﬂap defects in vitro. The
activity of size-fractionated FLAG-tagged BAFF 3-mers increased
~100-fold for human BAFF and 10-fold for mouse BAFF (WT or
histidine mutants) upon anti-FLAG antibody-mediated cross-
linking. The effect was even more pronounced with the glutamic
acid mutants (> 1000-fold for human and > 100-fold for mouse).
Upon cross-linking, all BAFF gained similarly high activities,
although the glutamic acid mutant remained about 3-fold less
active than the others (Fig. 4c, d). This could be explained if the
cross-linking antibodies cannot arrange BAFF 3-mers in the
signaling complex as precisely as via ﬂap–ﬂap interactions. The
anti-mouse BAFF antibody 5A8 (and to a lesser extent Sandy-5)
was as efﬁcient as anti-FLAG to activate mBAFF E247K assayed
on reporter cells (Fig. 4e), or on puriﬁed primary mouse B
splenocytes where 5A8 fully corrected the marked signaling defect
of mBAFF E247K (Fig. 4f). These results reinforce the conclusion
that mBAFF E247K can bind receptors but cannot signal, and
additionally demonstrated that a ﬂap defect can be overcome by
antibody-mediated cross-linking, in support of the model pre-
sented in Fig. 4a.
Anti-BAFF antibodies rescue ﬂap defects in knock-in mice.
Knock-in mice express ﬂap-deﬁcient BAFF that is competent for
receptor binding but impaired in signaling (Fig. 3). When these
mice were treated for 6 weeks with BAFF cross-linking antibodies
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Fig. 2 Flap mutations affecting 60-mer formation: one of them additionally affects activity of BAFF 3-mer. Naturally cleaved, untagged human or mouse
BAFF, with or without the indicated mutations in the ﬂap, were recovered in supernatant of 293 T cells transiently transfected with plasmids encoding the
full length wild type (WT) or mutant BAFF. Concentrated supernatants were fractionated by size-exclusion chromatography and fractions analyzed for the
presence of BAFF by western blot using anti-human or anti-mouse BAFF antibodies, and for the activity of BAFF at the indicated dilutions of fractions using
a hBAFFR:Fas reporter cell line that undergoes Fas-mediated killing upon stimulation of the chimeric receptor by BAFF. a Analysis of human BAFF WT and
mutants. White arrows points at fractions with peak activity of BAFF 3-mer and 60-mer, as indicated. b Analysis of mouse BAFF WT and mutants. The
experiment was performed twice for human BAFF and thrice for mouse BAFF
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(5A8 or Sandy-5), mature splenic B cells were signiﬁcantly
(p < 0.05 for Sandy-5 and p < 0.01 for 5A8, by one-way Anova)
increased compared to the control group or to BAFF-deﬁcient
mice (Fig. 5a, b, d, Supplementary Table 3). B cells also increased
in lymph nodes where the B to T cell ratio reached half or two
thirds of WT levels in mice treated with Sandy-5 or 5A8,
respectively (Fig. 5a, c, d).
These results reveal that knock-in mice contain a latent, inactive
form of BAFF that can be reactivated in vivo by cross-linking
antibodies. The repopulation of the B cell compartment proves that
endogenous mBAFF E247K protein in knock-in mice can bind and
activate BAFFR in vivo under adequate conditions, as seen in vitro
with the recombinant protein. This also reinforces the conclusion
that the ﬂap of BAFF has a function that is independent of, but as
crucial as receptor binding for the activity of BAFF. This
experiment however does not allow addressing the exact mechan-
ism of action of activating antibodies in vivo, which is likely to
depend both on activation of BAFF activity by cross-linking and on
the increased half-life of mBAFF bound to antibodies.
Belimumab and atacicept differentially inhibit BAFF 60-mer.
The anti-BAFF antibody, belimumab, is reported to inhibit
soluble BAFF only28. We wondered whether belimumab could
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Fig. 3 Reduced numbers of mature B cells in BAFF E247K knock-in mice despite normal circulating level of BAFF competent for receptor binding. a Relative
levels of circulating BAFF were measured in a homogeneous ELISA-like assay (AlphaLisa) using a pair of anti-mBAFF antibodies (5A8 and Sandy-2) in the
serum of Baffwt/wt (+/+) (n= 12), Baffwt/E247K (ki/+) (n= 20), and BaffE247K/E247K (ki/ki) (n= 16) littermates and in the serum of Baff−/− (−/−)
(n= 12) mice. Mean ± SEM. One-way Anova followed by Bonferroni comparing +/+ to other genotypes. NS= not signiﬁcant: p > 0.05; ***p < 0.001. The
experiment was performed twice. b Same as panel a, except that BAFF was measured with one soluble receptor (TACI-Fc) and one anti-mouse BAFF
antibody (Sandy-2). The experiment was performed once. c Flow cytometry analysis of lymphocytes with T cell (CD19−, CD93−), mature B cell (matB)
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followed by Bonferroni comparing +/+ to other genotypes. ***p < 0.001. f Same as panel e, but showing B to T cell ratio in lymph nodes. g Number of
mature B cells in spleens of mice (4 mice per group, 3 for WT, 5 for +/−) of the indicated genotypes, all littermates. Mean ± SEM. One-way Anova
followed by Bonferroni comparing +/+ to other genotypes. ***p < 0.001. The experiment was performed once in this format (and twice comparing +/+,
+/−, and −/−). h Same as panel g, but showing B to T cell ratio in lymph nodes. See also Supplementary Figs. 2, 3, and 4, and Supplementary Tables 1
and 2
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target the ﬂap of BAFF to prevent its signaling function. However,
both belimumab and atacicept (TACI-Fc) efﬁciently inhibited Fc-
BAFF, an intrinsically cross-linked (and therefore ﬂap-indepen-
dent) BAFF, indicating that belimumab is unlikely to target only
the ﬂap of BAFF (Fig. 6a, b). However, belimumab did not inhibit
naturally cleaved human BAFF, even when belimumab was used
at concentrations higher than those of atacicept (Fig. 6c, d).
As naturally processed human BAFF can form 60-mers
(Fig. 2a)22, we tested belimumab activity on puriﬁed BAFF 60-
mer, which belimumab also failed to inhibit (Fig. 6e, f), in line
with another report29. These experiments strongly suggest that
belimumab, unlike atacicept, does not (immediately) inhibit
BAFF 60-mer.
Belimumab inhibits BAFF 60-mer after dissociation to 3-mer.
As BAFF 60-mers are in equilibrium with BAFF 3-mers19,22,
belimumab should be able to inhibit BAFF 60-mer indirectly by
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regions relevant for 3-mer to 3-mer interactions. Residue numbering is for human BAFF. Brackets link residues with symmetric interactions (e.g., K216 of
one BAFF 3-mer interacts with E223 of another BAFF 3-mer and vice-versa, see also Fig. 1a), where acidic residues are shown in magenta, basic residues in
blue, and the tyrosine that pairs with His218 in turquoise. Hs: Homo sapiens; Mm: Mus musculus; Md: Monodelphis domestica; Gg: Gallus gallus; Ac: Anolis
carolinensis; Xt: Xenopus tropicalis; Lc: Latimeria chalumnae; Lo: Lepisosteus oculatus; Om: Oncorhynchus mykiss; Pf: Poecilia formosa; Dr: Danio rerio; Cm:
Callorhinchus milii; Pm: Petromyzon marinus. c Cell viability measured in BAFFR:Fas reporter cells exposed to the indicated concentrations of FLAG-hBAFF
WT or mutants in the presence of a ﬁxed concentration of a control antibody (EctoD1) or of an anti-FLAG cross-linking antibody. The experiment was
performed twice. d Same as panel c, but for FLAG-mBAFF. The experiment was performed twice. e Same as panel d, but for FLAG-mBAFF E247K in the
presence of a constant concentration of a control antibody (EctoD1), of a cross-linking antibody (anti-FLAG), or of cross-linking anti-mBAFF monoclonal
antibodies (5A8 and Sandy-5). The experiment was performed twice. f Cell viability of primary splenic mouse B cells cultured for 3 days in the presence of
titrated amounts of FLAG-mBAFF WT or E247K, alone or in the presence of ﬁxed amounts of control (EctoD1) or cross-linking (5A8, Sandy-5) antibodies.
Each point is the mean ± SEM of technical triplicates. Experiment performed once in this format (and once with less titration points)
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capturing BAFF 3-mers released upon dissociation. To test this
hypothesis, BAFF 60-mer was incubated for 3 days at 37 °C with
or without belimumab or atacicept. BAFF 60-mer alone retained
full activity under these conditions (Fig. 6g) and atacicept
inhibited BAFF 60-mer both directly and after co-incubation
(Fig. 6h). Belimumab did not signiﬁcantly inhibit BAFF 60-mer
when used directly, but could do so, after a co-incubation of
3 days, although still less efﬁciently than atacicept (Fig. 6i). In
another experiment, belimumab was incubated with an excess of
BAFF 60-mer, with the expectation that binding to BAFF 60-mer
or to BAFF 3-mer would differently shift the size of belimumab.
In this experiment, the elution position of belimumab was indeed
shifted, but remained smaller than that of BAFF 60-mer still
present in the mixture (Supplementary Fig. 5). Taken together
these results indicate that belimumab cannot inhibit BAFF 60-
mer directly, but can eventually do so when BAFF 60-mer dis-
sociates into 3-mers.
3D elucidation of the mechanism of action of belimumab. The
antigen-binding fragment (Fab) of belimumab was produced by
digestion with papain, while BAFF 3-mer was expressed in pro-
karyotic cells. To prevent association of BAFF 3-mer into 60-mer,
mutation H218A was introduced into the ﬂap region22, which did
not grossly affect the afﬁnity of belimumab for BAFF (Supple-
mentary Fig. 6). BAFF 3-mer or the Fab taken alone had roughly
equal native sizes (Fig. 7a–c), but formed a larger, well-deﬁned
complex when BAFF was mixed with an excess of belimumab Fab
(Fig. 7d). Some free Fab was detected when the complex was re-
analyzed by size-exclusion chromatography (Fig. 7e), suggesting
that the Fab was not very tightly bound to BAFF.
As expected, the high-molecular-weight complex contained
both BAFF and the Fab when analyzed by reducing or non-
reducing SDS-PAGE (Fig. 7f). The BAFF–Fab complex was
analyzed by both electron microscopy and crystallography
(Supplementary Fig. 7, Supplementary Table 4). Negative stain
electron microscopy images often revealed structures with three
arms on which the crystal structure could readily be super-
imposed (Fig. 7g, h). The complex sometimes also appeared as L-
shaped, which could be interpreted either as a complex with 3
Fab, one of which would stand perpendicular to the image plane,
or as a BAFF 3-mer bound to only two Fab (Fig. 7i, j). Incomplete
complexes with a single Fab bound to a BAFF 3-mer could also be
seen (Fig. 7k). This less abundant form was likely excluded from
crystals where only BAFF bound to three Fabs could be observed.
Interestingly, the relative instability of the BAFF–Fab complex
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Fig. 5 Restoration of mature B cells in BAFF E247K knock-in mice treated with cross-linking anti-mBAFF antibodies. Cohorts of BAFF E247K knock-in mice
received control (EctoD1) or BAFF cross-linking antibodies (Sandy-5 or 5A8) weekly for 6 weeks, then spleen and lymph nodes were analyzed for the
presence of mature B cells. Groups of untreated wild type (WT) and BAFF knock-out (KO) were analyzed in parallel. a Flow cytometry analysis of spleen
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was suggested by the observation that the puriﬁed complex was
almost as active as BAFF alone on reporter cells, which could be
explained either by the existence of a small proportion of free
BAFF, or by competition of high-afﬁnity BAFFR with Fab for a
common binding site on BAFF (Fig. 7l).
A closer look at the structure of the BAFF–belimumab Fab
complex showed that both heavy and light chains of belimumab
contacted BAFF over its entire height, forming two distinct
interfaces with the receptor-binding site (664 Å2) and the ﬂap
region (333 Å2), for a total average surface area of 995 Å2
(963–1014 Å2 for the six copies of the asymmetric unit) (Fig. 8a).
In contrast, in a model of TACI bound to BAFF, the receptor
bound to a much smaller region of BAFF (Fig. 8b) that was clearly
separated from the ﬂap–ﬂap interaction region mediating BAFF
60-mer formation (Fig. 8c).
The BAFF–Fab complex is the ﬁrst structure in which BAFF 3-
mers make no contact with adjacent BAFF 3-mers via ﬂap–ﬂap
interactions. Nevertheless, the conformation of the ﬂap loop was
virtually identical to that of a ﬂap engaged in 3-mer to 3-mer
contacts, indicating that its conformation is constitutive and not
induced by binding (Fig. 8d). In addition, mutation H218A did
not grossly alter conformation of the ﬂap (Fig. 8d). Belimumab
made important contacts with a small cavity of BAFF that
normally accommodates the DXL loop motif present in all
natural receptors of BAFF and that is essential for receptor–ligand
interactions30. In fact, one of the variable loops of the heavy chain
of belimumab contained a DXL (DLL) motif that perfectly
mimicked the receptor-binding site, while the rest of the antibody
had no structural similarity with TACI or other BAFF receptors
(Fig. 8e, Supplementary Fig. 8). Finally, the light chain of
belimumab contacted a region of BAFF not involved in
interactions with the natural receptors. Fitting the structure of
the Fab of belimumab on BAFF 60-mer resulted in a clash area
of about 700 Å2 with BAFF (Fig. 8f) that would preclude binding
of belimumab to BAFF 60-mer. Taken together, these data show
that belimumab hijacks the natural receptor-binding site of BAFF
via a DXL motif in its heavy chain, but that the bulky nature of
the Fab and the additional contacts made by the light chain with
BAFF prevent interactions with BAFF 60-mer.
Atacicept binds to the surface of intact BAFF 60-mers. BAFF
60-mer migrated with a high molecular weight by size-exclusion
100
1
0.
1
0.
01 10
0
10
100
0
%
 v
ia
bi
lit
y 
of
B
A
F
F
R
:F
as
re
po
rt
er
 c
el
ls
%
 v
ia
bi
lit
y 
of
B
A
F
F
R
:F
as
re
po
rt
er
 c
el
ls
%
 v
ia
bi
lit
y 
of
B
A
F
F
R
:F
as
re
po
rt
er
 c
el
ls
Fc-BAFF [ng/ml]
Atacicept
[ng/ml]
10
0
5
1
0.
1
0.
01 10
0.
00
1
BAFF 60-mer [ng/ml]Naturally cleaved BAFF 
[fold conc S/N]
100
0
0
10
100
Belimumab
[ng/ml]
80
a
b
c
d
e
f
10
–2
10
–4
10
–6
10
–8
0.
1 10
0.
00
1
BAFF 60-mer [ng/ml]
100
0
3 days,
then
inhibitor
Inhibitor,
then
3 days
ihg
10
–5
0.
1 10
0.
00
1
10
–5
0.
1 10
0.
00
1
10
–5
No inhibitor
Atacicept
100 ng/ml 
Belimumab
100 ng/ml 
Fresh
3 days
at 37 °C
No inhibitor
Fig. 6 Belimumab differs from atacicept in that it does not inhibit BAFF 60-mer promptly. BAFF-responsive BAFFR:Fas reporter cells were treated overnight
with titrated amounts of the indicated forms of BAFF, in the presence or absence of the inhibitors atacicept or belimumab at ﬁxed concentrations. Cell
viability was then monitored. a, b Inhibition of Fc-BAFF by atacicept (a) or belimumab (b). The experiment was performed 3 times. c, d Naturally processed
hBAFF in supernatants of transfected 293 T cells exposed to atacicept at 0 or 5 ng/ml (c) or belimumab at 80 ng/ml (d). The experiment was performed
twice. e, f Inhibition of Fc-BAFF by atacicept (e) or belimumab (f). The experiment was performed 3 times. g BAFF 60-mer was titrated in medium, then
incubated in medium for 3 days at 37 °C, then added to reporter cells. Alternatively, BAFF 60-mer was titrated in medium just before the assay (fresh). h, i
BAFF 60-mer was titrated in medium without or with atacicept (h) or belimumab (i) for 3 days at 37 °C. Samples without inhibitors received inhibitor or
not after 3 days of incubation. Samples were then added to reporter cells. The experiment was performed twice. Panels a, b, e, and f show the mean ± SEM
of 5 replicates, panels c and d of duplicate, and panels g, h and i of triplicate measures. The condition without inhibitor is the same in panels a and b, in
panels c and d, in panels e and f, and in panels g, h, and i. See also Supplementary Fig. 5
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chromatography (Fig. 9a, b). When BAFF 60-mer was mixed
with an excess of atacicept on ice, a heavy precipitate formed,
and the supernatant only contained excess soluble atacicept with
no trace of complex (Fig. 9c). However, when resuspended in
buffer, the precipitated complex reversibly dissolved at room
temperature and re-precipitated on ice (Fig. 9d). The
atacicept–BAFF 60-mer complex could therefore be isolated by
size-exclusion chromatography at room temperature (Fig. 9e, f).
Analysis of BAFF 60-mer by electron microscopy revealed a well-
organized, capsid-like structure of about 220 Å diameter (Fig. 9g,
pictures on the left)19. In the presence of atacicept, these particles
enlarged to a diameter of about 340 Å, indicating that they had
been coated with atacicept without affecting assembly of the
underlying BAFF 60-mer (Fig. 9g, pictures on the right). We
conclude from these studies that although atacicept and beli-
mumab share common features for BAFF binding (the DXL
motif), they differ by their binding ability to un-dissociated BAFF
60-mer.
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Potential impact of distinct anti-BAFF drugs speciﬁcities. In
the present study, the structural basis for the distinct inhibitory
mechanisms of BAFF 60-mer by belimumab and atacicept was
characterized. This is not the only difference between belimumab
and atacicept regarding their substrate speciﬁcity: atacicept, but
not belimumab, also inhibits APRIL, and heteromers of BAFF
and APRIL31. Whether these differences positively or negatively
impact the therapeutic action of these drugs is unknown. This will
depend on whether drug targets are expressed or not in the
pathological context, and also on how detrimental pathogenic
cells (e.g., autoreactive or pro-inﬂammatory cells) and useful
protective cells (e.g., normal plasma cells or regulatory cells)
overlap with their requirements for potentially distinct sets of
survival factors and for the set of receptors (BAFFR, TACI, and
BCMA) used to respond to them. For example, if a subset of
autoreactive plasma cells are pathogenic in human SLE, and these
cells require either BAFF or APRIL, like normal mouse plasma
cells32, atacicept could be superior to belimumab. But if this same
pathogenic cell subset would turn out to require BAFF only,
atacicept could induce an unnecessary immunodeﬁciency. With
regard to BAFF 60-mer, about which almost nothing is known in
humans, much work is still needed to understand whether and
where this complex occurs, and for which physiological or
pathological functions. Also, the different mechanisms of BAFF
60-mer inhibition characterized in this study could be irrelevant
in vivo if BAFF 60-mer dissociates into 3-mers before it can act
on target cells, or crucial if newly synthetized BAFF 60-mer can
reach its target before dissociation.
Modulation of TNF family ligand activity by oligomerization.
It has long been recognized that membrane-bound and soluble
TNF differentially activate TNFRSF1A (TNFR1) and TNFRSF1B
(TNFR2) and fulﬁll different functions in inﬂammation and
immunity to mycobacteria33–35. Similarly, membrane-bound and
soluble TNF ligand superfamily member 6 (FasL) have different
capacities to induce either apoptosis or non-deadly functions such
as cell migration (reviewed in ref. 36). Membrane-bound ligands
can only deliver signals in a cell-to-cell contact but can activate
receptor functions more efﬁciently than soluble ligands. In con-
trast, soluble ligands can act systemically but require receptors
responsive to such soluble ligands. The plasma membrane is
believed to cluster membrane-bound ligands, a function that can
be mimicked when soluble ligands are either cross-linked or
engineered to contain two trimers within a single molecule37.
Ectodysplasin-A (EDA), the only TNF family ligand containing a
collagen domain, must be processed to a soluble form to fulﬁll its
functions in the embryonic development of skin-derived appen-
dages38. In this case, it is the collagen domain that mediates an
intrinsic oligomerization to make soluble EDA efﬁcient activators
of their oligomerization-sensitive receptor39. BAFF is another
ligand with an intrinsic propensity to oligomerize, but this time as
a 60-mer. BAFF 60-mer, or membrane-bound BAFF, might be
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required to activate TACI and possibly BCMA20. In contrast,
BAFFR can also be stimulated by BAFF 3-mer and, in that
respect, resembles TNFR1 activated by soluble TNF. We now
suggest that the ﬂap of BAFF clusters individual complexes of
BAFF 3-mer/BAFFR to form multimers endowed with the
capacity to initiate relevant B cell survival signals in vitro and
in vivo. Clustering of individual BAFF-BAFFR signaling units
probably represents the primary and sine qua non function of the
ﬂap of BAFF, while the capacity of the ﬂap to assemble BAFF 60-
mer could be a secondary improvement of this oligomerizing
function.
In summary, binding and activation of BAFFR by BAFF are
distinct steps. With regard to BAFF-directed therapies, the ﬂap of
BAFF should be considered as a target potentially as good as the
receptor-binding site for BAFF inhibition. Conversely, stimulat-
ing BAFF activity by promoting oligomerization could prove
beneﬁcial in certain immune deﬁciencies. Finally, the ﬂap of
BAFF not only controls BAFF signaling (via 3-mer to 3-mer
interactions) and BAFF potency (via 60-mer formation), but can
also interfere with the binding and action of anti-BAFF drugs.
Methods
Animals. Baff−/− mice were as described12,20. C57BL/6OlaHsd mice were pur-
chased from Envigo (Horst, Netherlands, stock# 057) and housed in a speciﬁc
pathogen-free animal facility. BAFF E247K knock-in mice were generated
according to standard procedures. Brieﬂy, embryonic stem cells (129 SvEv) were
electroporated with a construct containing the E247K mutation (GAG CTG →
AAG CTT) in exon 6 of Baff and a ﬂoxed NeoR cassette inserted in introns 6–7 and
screened by PCR and Southern blot for homologous recombination events (Sup-
plementary Fig. 2). Recombined embryonic stem cells were injected into C57BL/6
blastocysts followed by transfer into the uterus of pseudo-pregnant recipients.
Progeny of chimeric mice that transmitted the mutation was backcrossed for 4
generations onto the C57BL/6 background, then bred to B6.C-Tg(CMV-cre)1Cgn/J
mice (sn#006054, The Jackson Laboratory) to remove the NeoR cassette.
Heterozygous mice were bred to obtain cohorts of Baffwt/wt, Baffwt/E247K, and
BaffE247K/E247K littermates, or bred to Baff−/− to obtain cohorts of Baffwt/wt,
Baffwt/–, Baffwt/E247K, and BaffE247K/− littermates. Experiments were performed
according to guidelines and under the authorization of the Swiss Federal Food
Safety and Veterinary Ofﬁce (authorization 1370.6 to PS).
Genotyping. Ear biopsies were digested for 2–16 h at 55 °C in 50 µl of the
DirectPCR Lysis Reagent (Peqlab, 31-102-T) plus 2 µl of Proteinase K (Roche),
followed by 45 min at 85 °C. Supernatants of BAFF-E247K ki lysates were used for
PCR using primers fwd 5ʹ-ACCCTGTTCCGATGTATTCA-3ʹ and rev 5ʹ-TAA-
GAGAGTGCCAGGTCCC-3ʹ, with 30 cycles of 94 °C (7 s)/58 °C (20 s)/72 °C (40
s). Supernatants of BAFF-ko lysates were used for PCR using primers wt shared 5ʹ-
GCAGATTGAGCAATCCATGGAAGGCCA-3ʹ, wt speciﬁc 5ʹ-CAAGTTGATG
TCCTGACCCAAGGCACC-3ʹ, and neo 5ʹ-TGGCAGGGTCTTTGCAGACTC
ATCCAT-3ʹ, with 30 cycles of 94 °C (7 s)/60 °C (20 s)/72 °C (20 s). For the
screening of recombined ES cells, genomic DNA was ampliﬁed with primers NeoR
fwd 5ʹ-CCTTCTATCGCCTTCTTGAC-3ʹ and BAFF rev 5ʹ-GTGGAACAGATAA
GGTGCCT-3ʹ, with 3 cycles of 95 °C (30 s)/64 °C [ramp-0.5 °C/cycle] (30 s)/68 °C
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was soluble at room temperature but that reversibly precipitated on ice. The atacicept–BAFF 60-mer complex was isolated by size-exclusion
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mer–atacicept complex (re-solubilized precipitate, before size-exclusion chromatography; ~17 µg). The complex was also analyzed under reducing (+DTT)
and non-reducing (−DTT) conditions. This analysis was performed twice. g Three representative negative stained electron microscopy pictures of BAFF
60-mer alone (left column) or of BAFF 60-mer–atacicept complexes (right column). This analysis was performed once. Scale bar: 400 Å
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(2 min), followed by 30 cycles of 95 °C (30 s)/54 °C (30 s)/68 °C (2 min), using
TaKaRa LA polymerase (TaKaRa) at 5 U/ml.
Reagents and cell lines. The following antibodies were used: mouse IgG1 anti-
FLAG M2 and biotinylated M2 (Sigma Aldrich F3165 and F9291), goat IgG 852
anti-mouse BAFF (R&D AF2106), biotinylated mouse IgG1 anti-human BAFFR
huBR9.1 (Adipogen, Liestal, Switzerland, AG-20B-0016B), rat IgG1 anti-mouse
BAFF 5A840, mouse IgG1 anti-mouse BAFF Sandy-2 and Sandy-541, rat IgM anti-
human BAFF Buffy-29, and mouse IgG1 anti-EDA EctoD142. Human IgG1 anti-
human BAFF antibody belimumab (registered trade name Benlysta) was purchased
from the Pharmacy of Lausanne University Hospital (CHUV). hBAFFR-Fc was
from Adipogen (AG-40B-0027) and hTACI (aa 31–110)-hIgG1 Fc (aa 245–470,
L258E, A353S, P354S) (atacicept) was provided by Merck, KGaA. HEK 293, HEK
293 T, Jurkat, and BJAB cells were obtained from late Jürg Tschopp (University of
Lausanne). CHO-S cells were from Thermoscientiﬁc (A1155701). Reporter cells
Jurkat-JOM2-hBAFFR:Fas clone 2131,43,44 were as described and grown in RPMI
supplemented with 10% fetal calf serum (FCS). HEK 293 T cells were grown in
DMEM 10% FCS. BJAB and BJAB–TACI cells45 were grown in RPMI supple-
mented with 10% FCS. Cell lines were tested for mycoplasma using MycoAlert
mycoplasma detection kit (Lonza, LT07-318) and found to be negative. As the
identity of CHO-S, HEK 293, HEK 293 T, and Jurkat cells does not impact on
result interpretation, these cell lines were not authenticated. The identity of BJAB
cells was conﬁrmed by microsatellite sequencing (cell line typing service,
Microsynth, Balgach, Switzerland).
Immunoglobulin-depleted fetal calf serum. A volume of 500 ml of FCS was
depleted from immunoglobulins by repeated passages (usually eight times) at 4 ml/
min on a 5 ml Protein A-Sepharose column (GE Healthcare), until the fraction of
immunoglobulins bound to the column became negligible. Immonoglobulin-
depleted serum was sterilized by ﬁltration at 0.2 µm.
Puriﬁcation of Fc-containing recombinant protein. Fc-containing proteins (from
plasmids listed in Supplementary Table 5) were produced from stable clones of
HEK 293 or CHO-S cells. Cells were grown in serum-free OptiMEM medium or in
DMEM/F12 (1:1, v/v) medium supplemented with 2% of immunoglobulin-
depleted FCS. Proteins in conditioned supernatants were afﬁnity-puriﬁed on 5 ml
(or 1 ml) Protein A- or Protein G-Sepharose column (GE Healthcare), eluted with
50 mM citrate-NaOH pH 2.7 and neutralized with appropriate amounts of 1 M
Tris–HCl pH 9. Proteins were concentrated, and buffer exchanged for PBS using
30 kDa cutoff centrifugal devices, then sterilized by ﬁltration at 0.2 µm, quantiﬁed
by absorbance at 280 nm using theoretical molar extinction coefﬁcients and stored
at −70 °C until use44,46.
Puriﬁcation of His-tagged BAFF. Escherichia coli M15 pRep4 bacteria expressing
His-tagged hBAFF H218A (3-mer) and His-tagged hBAFF (60-mer)21 in early
logarithmic phase of growth were grown overnight at 18 °C in L-Broth medium
supplemented with 0.1 mM of isopropyl-thiogalactoside. Bacteria were harvested,
lysed by sonication in 30 ml of 10 mM Tris–HCl pH 8, 0.5 M NaCl per liter of
culture and insoluble material was removed by centrifugation (15 min, 17,000 × g).
Supernatants were loaded (up to three liter equivalent of culture) on a 5 ml
chelating-Sepharose column (GE Healthcare) pre-loaded with 0.5 M ZnSO4 and
equilibrated in lysis buffer. The column was washed with two volumes of 10 mM
Tris–HCl pH 7.4, 150 mM NaCl (TBS), ﬁve volumes of TBS 50 mM imidazole, two
volumes of TBS, and eluted with three volumes of TBS, 50 mM ethylenediami-
netetraacetic acid (EDTA). Proteins were concentrated (30 kDa cutoff) and frac-
tionated by size-exclusion chromatography on a Superdex 200 column as described
under 'size-exclusion chromatography'. Fractions corresponding to BAFF 3-mer or
BAFF 60-mer were ﬁlter-sterilized, quantiﬁed by absorbance at 280 nm and stored
at −70 °C.
Generation of the Fab fragment of belimumab. Quantity of 120 mg of belimu-
mab was mixed with 500 μl of immobilized papain beads (ThermoScientiﬁc) in 3
ml of 20 mM cysteine, 20 mM Na-phosphate pH 7, 10 mM EDTA, and digested for
4 days at 37 °C. At the end of the incubation, beads were removed and the Fab was
recovered in the ﬂowthrough of a Protein A afﬁnity column. Fab were concentrated
on 10 kDa cutoff centrifugal devices, then size-fractionated on a Superdex 200
Increase column in 20 mM Hepes pH 7.5, 130 mM NaCl.
Relative afﬁnity of belimumab Fab for Fc-BAFF WT and H218A. Quantity of
300 µg of belimumab Fab in 300 µl of 0.1 M Na-borate pH 8.8 was biotinylated for
2 h at room temperature with 3 µl of sulfo-N-hydroxysuccinimide-LC-biotin
(Pierce, 21335) at 30 µg/ml in DMSO. Reaction was terminated by addition of 10 µl
of 1 M NH4Cl, and buffer was exchanged to PBS using a 30 kDa cutoff centrifugal
device. Fc-hBAFF (WT or H218A, 100 µl) was coated at 1 µg/ml in PBS in an
ELISA plate. After blocking, 50 µl of soluble Fc-BAFF (WT or H218A) were added
at 2-fold the desired ﬁnal concentration, followed by the addition of 50 µl of 100
ng/ml biotinylated Fab of belimumab and immediate mixing. After washing, bound
Fab was detected with horseradish peroxidase-coupled streptavidin.
Complex between BAFF 3-mer and the Fab of belimumab. Quantity of 8.8 mg of
His-hBAFF H218A was mixed with 50 mg of the Fab fragment of belimumab in 20
mM Hepes pH 7.5, 130 mM NaCl, incubated for 16 h at 4 °C, and size-fractionated
by size-exclusion chromatography in the same buffer. Fractions of complex were
concentrated to 28 mg/ml.
Generation of a complex between BAFF 60-mer and atacicept. Quantity of 0.9
mg of His-hBAFF 60-mer at 4.6 mg/ml was mixed with 9.7 mg atacicept at 75 mg/
ml in 20 mM Hepes pH 8.2, 130 mM NaCl and incubated for 1 h on ice. The
precipitate was recovered by centrifugation at 4 °C, then re-dissolved at room
temperature in 20 mM Hepes pH 8.2, 130 mM NaCl and size-fractionated at room
temperature by size-exclusion chromatography in the same buffer. Fractions of the
complex were concentrated to 0.8 mg/ml.
Transfections. HEK 293 T cells were transiently transfected with the poly-
ethyleneimide method47 and grown for 7 days in serum-free OptiMEM, after
which time supernatants were harvested and concentrated 20 times in 30 kDa
cutoff centrifugal concentration devices.
Generation of BAFFR-deﬁcient cell lines. BJAB and BJAB-TACI cells deﬁcient
for BAFFR were generated by lentiviral transduction of a CRISPR/Cas9-expression
vector carrying a hBAFFR gRNA (Supplementary Table 5). Annealed oligonu-
cleotides 5ʹ-CACCGGGCCGAGTGCTTCGACCTGC-3ʹ and 5ʹ-
AAACGCAGGTCGAAGCACTCGGCCC-3ʹ were cloned in the BsmBI restriction
site of lentrcrispr v2 plasmid (Supplementary Table 5)48. This plasmid was co-
transfected with co-vectors pCMV-VSV-g and psPAX2 (Supplementary Table 5)
into 293 T cells with polyethyleneimide. The next day, cells were washed with PBS
and cultured for an additional day in RPMI 10% FCS. Cell supernatants ﬁltered at
0.45 µm were supplemented with 8 µg/ml polybrene (Sigma, H9268) and 3 ml were
added to 2 × 106 pelleted target cells that were subsequently cultured overnight in a
12-well plate, then expanded for 2 days in a 6-well plate. Cells were then submitted
to two rounds of selection in RPMI 10% FCS, 1 µg/ml puromycin (EnzoLi-
feSciences). Surviving cells were cloned in RPMI 10% FCS. BAFFR-deﬁcient clones
were identiﬁed by ﬂow cytometry after staining with biotinylated huBR9.1 at 2 µg/
ml, followed by PE-coupled streptavidin at 1/500.
Size-exclusion chromatography. Size-exclusion chromatography was performed
at a ﬂow rate of 0.6 ml/min on a Superdex 200 Increase HR 10/30 column equi-
librated in either PBS, or 20 mM Hepes pH 7.5, 130 mM NaCl, or 20 mM Hepes
pH 8.2, 130 mM NaCl, as indicated. The column was calibrated with 100 µl of a
mixture of ferritin (440 kDa) at 140 µg/ml and thyroglobulin (669 kDa), aldolase
(158 kDa), ribonuclease A (13.7 kDa) (all from GE Healthcare), bovine serum
albumin (67 kDa), ovalbumin (43 kDa), carbonic anhydrase (29 kDa), and apro-
tinin (6.5 kDa) (all from Sigma-Aldrich) at 1.4 mg/ml in PBS.
Western blot and quantiﬁcation of BAFF. SDS-PAGE and western blot (using
Buffy-2 at 0.5 µg/ml for human BAFF, 852 at 0.5 µg/ml for mouse BAFF and a
peroxydase-coupled donkey anti-human IgG for belimumab) were performed
according to standard procedures, using WesternBright ECL spray for detection
(Advansta) (Supplementary Fig. 9). For the detection of BAFF in fractions of size-
exclusion chromatography, proteins were precipitated for 10 min on ice with 5%
trichloroacetic acid and 300 µl equivalent of fraction was used for western blot.
Coomassie blue staining was performed with a semidry iD Stain System (Euro-
gentech). WT forms of puriﬁed FLAG-mBAFF and FLAG-hBAFF were quantiﬁed
by SDS-PAGE and Coomassie blue staining against a standard curve of His-BAFF
60-mer41. They were used as standards to quantify FLAG-tagged BAFF 3-mers in
Superdex-200 fractions (fraction 13+ 14 for mBAFF and 15+ 16 for hBAFF) and
naturally cleaved BAFF in concentrated supernatants by western blot using bioti-
nylated anti-FLAG M2 antibody (0.5 µg/ml) followed by IRDye 800CW-coupled
streptavidin (100 ng/ml in PBS, 0.5% Tween-20, 1% powdered milk), or Buffy-2
(0.5 µg/ml) followed by IRDye anti-rat (100 ng/ml) or 852 (0.5 µg/ml) followed by
IRDye anti-goat (100 ng/ml), and detection with a LI-COR Odyssey infrared
ﬂuorescence detector (LI-COR Biosciences).
Cytotoxic assays with BAFFR:Fas reporter cells. Untagged BAFF in fractions of
the size elution column were tested at the indicated dilutions. 3-mer fractions of
FLAG-tagged BAFF were tested at the indicated concentrations, in the presence of
a ﬁxed concentration of 1 µg/ml of cross-linking (anti-FLAG, 5A8, Sandy-5) or
control (EctoD1) antibodies. Fc-BAFF and BAFF 60-mer were tested at the indi-
cated concentrations. When inhibitors were present, they were added at the
indicated concentrations and, unless stated otherwise, pre-incubated for several
minutes with ligands (in a ﬁnal volume of 50 µl medium) before addition of 50 µl of
reporter cells (20,000–50,000 cells/well). Reporter cells were incubated with BAFF
for 16 h, then assayed for viability by the addition of 20 µl of a solution of phe-
nazine methosulfate at 0.9 mg/ml in PBS and 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium at 2 mg/ml in PBS
(1:20, v/v) (PMS/MTS), followed by further incubation at 37 °C until adequate
color development (2–8 h). Absorbance was measured at 490 nm44.
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Receptor–ligand interaction ELISA. For the direct-binding ELISA, BAFFR-Fc,
BCMA-Fc, or TACI-Fc (human or mouse) were adsorbed at 1 µg/ml in PBS
overnight at room temperature into 96-well immunoplates. The following steps
were then performed, with incubations at 37 °C: blocking (in PBS, 4% powdered
skimmed milk, 0.5% Tween-20), washing (in PBS, 0.05% Tween-20), incubation
with FLAG-tagged BAFF 3-mers of the corresponding species at the indicated
concentrations for 1 h (in incubation buffer: PBS, 0.4% milk, 0.05% Tween-20),
washing, incubation with biotinylated anti-FLAG at 0.5 µg/ml in incubation buffer
for 1 h, washing, incubation with horseradish-coupled streptavidin at 1/4000
dilution in incubation buffer, washing, incubation with 100 µg/ml of 3,3ʹ,5,5ʹ-tet-
ramethylbenzidine in 50 mM citrate-phosphate pH 5, 10% DMSO, 0.03% perborate
until color development, addition of 1/3 volume of 2M H2SO4, and absorbance
reading at 405 nm44. For the competitive ELISA, titrated amounts of naturally
cleaved (untagged) wild-type BAFF were added to adsorbed BAFFR-Fc for 30 min,
followed without intermediate washing steps by a ﬁxed and non-saturating
concentration of FLAG-tagged BAFF 3-mers (10 ng/ml for human and 50 ng/ml
for mouse). Detection with biotinylated anti-FLAG was performed as described for
the direct-binding ELISA.
AlphaLISA. BAFF in mouse sera was detected by AlphaLISA in white 384-well
plates41. 5 µl of serum diluted 1:10 in assay buffer (PerkinElmer Life Sciences) was
added to 20 µl of a mix of biotinylated Sandy-2 antibody at 75 ng/ml and 0.5 µg of
5A8-coupled acceptor beads in assay buffer and incubated for 1 h at room tem-
perature. Streptavidin-coupled donor beads (1 µg) in 25 µl assay buffer was added.
15 min later, emission at 615 nm after excitation at 680 nm was measured with an
Enspire plate reader (PerkinElmer Life Sciences).
hTACI-Fc (100 µg) was mixed to 1 mg of AlphaLISA acceptor beads in 400 µl of
27 mM Na-phosphate pH 8, 5 mM NaBH3CN, 0.03% Tween 20 and incubated for
24 h at 37 °C with agitation, after which time coupling was stopped by addition of
100 µl of carboxymethoxylamine at 65 mg/ml in 0.8 M NaOH for 1 h at 37 °C.
Beads were washed twice in 0.1 M Tris–HCl, pH 8 and stored at 4 °C at a
concentration of 5 mg/ml in PBS 0.05% Proclin-300. Measures of receptor binding-
competent BAFF were performed by mixing 5 µl of mouse serum with 1.5 µg of
hTACI-Fc acceptor beads in assay buffer for 3 h at room temperature. Beads were
harvested for 10 min at 8000 rpm (6200 × g), washed with assay buffer, suspended
in 25 µl of 0.45 µg/ml biotinylated Sandy-2, transferred in white 384-well assay
plates, incubated for 1 h at room temperature, after which time 1.5 µg of
streptavidin-coupled donor beads in 25 µl of assay buffer was added. Emission at
615 nm after excitation at 680 nm was recorded with an Enspire plate reader
(Perkin Elmer).
Mice treatments. For B cell stimulation experiments, Sandy-5, 5A8, or EctoD1
(control) antibodies were administered i.p. to BaffE247K/E247K mice at 2 mg/kg on
days 0, 7, 14, 21, 28, and 35. Mice were killed by CO2 exposure at day 42 for the
analysis of spleens and lymph nodes (inguinal, axillary, and brachial).
Flow cytometry. Secondary lymphoid organs were homogenized. Red blood cells
were lysed for 5 min on ice in 150 mM NH4Cl, 10 mM NaHCO3, 100 µM Na2-
EDTA. Lymphocytes were washed in PBS 2% FCS and ﬁltered on a nylon mesh.
Cells were incubated with antiCD16/32 (Fc-block, clone 93, 1/100, eBiosciences)
and stained with a mix of anti-CD19-PE.Cy7 (clone eBio1D3, 1/200, eBiosciences),
anti-CD93-biot (mAb493, 1/100, prepared in-house by Antonius Rolink), anti-
CD1d-FITC (clone 1B1, 1/100, eBiosciences), and anti-CD3-APC (clone 17A2, 1/
100, eBiosciences) for 20 min at 4 °C followed by PE-Cy5.5-coupled streptavidin (1/
200) and analysis with a FACS Canto (BD Biosciences). Data were analyzed with
the FlowJo software.
Mouse B splenocyte survival assay. Mouse splenocytes were puriﬁed with an
EasySepTM mouse isolation kit (StemCell Technologies, #19854). Puriﬁed B sple-
nocytes were labeled for 8 min at 37 °C in PBS, 1% FCS, 2 µM carboxyﬂuorescein
succinimidylester (CFSE) and cultured in round-bottomed 96-well culture plates, at
a density of 1.25 × 106 cells/ml in 200 µl of medium (RPMI, 10% FCS, 50 µM of 2-
mercaptoethanol, 100 U/ml of penicillin, and 100 µg/ml of streptomycin medium)
with titrated amounts of size-fractionated FLAG-mBAFF trimer in the presence or
absence of 1 µg/ml of cross-linking (5A8, Sandy-2) or control (EctoD1) antibodies.
After 72 h, cells were stained with 100 ng of propidium iodide per sample and
analyzed by ﬂow cytometry using an AccuriC6 ﬂow cytometer (BD Bioscience).
The percentage of viable cells was calculated as the number of live cells (CFSE+, PI-)
divided by the number of cells (CFSE+) × 10041.
Crystallography. Crystals of His6-hBAFF H218A in complex with three Fab
fragments of belimumab were obtained by mixing 0.1 µl protein solution (28 mg/
ml in 20 mM Hepes pH 7.5, 150 mM NaCl) with 0.1 µl reservoir solution (9% (w/v)
PEG4000, 0.1 M MgCl2, 0.1 M HEPES pH 7.5) using the sitting drop vapor dif-
fusion method at 293 K. Before ﬂash cooling in liquid nitrogen, crystals were cryo-
protected by reservoir solution supplemented with 20% (v/v) ethylene glycol.
Diffraction data were collected at 100 K at the Swiss Light Source beamlight
X06SA (SLS, Villigen, Switzerland) using an Eiger X 16M detector (Dectris, Baden-
Daettwil, Switzerland). Data were processed to 2.9 Å resolution using the programs
XDS and XSCALE49. The crystals belong to space group P 21 with a solvent content
of 64% (Matthews coefﬁcient 3.45). They contain 2 hexameric complexes per
asymmetric unit. Each complex, consisting of a BAFF 3-mer bound by 3 Fab
fragments of belimumab, has a 3-fold non-crystallographic symmetry. The phase
information necessary to determine and analyze the structure of the BAFF -
belimumab Fab complex was obtained by molecular replacement using the
program PHASER50 and the published structures of BAFF 3-mer (PBD-ID 1KD7)
and of an Fab fragment (PDB-ID 7FAB). Subsequent model building and
reﬁnement was performed with the software packages CCP4 and COOT51,52. For
the measure of the free R-factor, a measure to cross-validate correctness of the ﬁnal
model, about 0.6% of measured reﬂections were excluded from the reﬁnement
procedure (Supplementary Table 4). Several rounds of manual model building in
COOT and bulk solvent correction, positional, B-factor and TLS reﬁnement using
REFMAC yielded the ﬁnal model51,52. The Ramachandran Plot of the ﬁnal model
shows 89.4% of all residues in the most favored region, 10.0% in the additionally
allowed region, and 0.5% in the generously allowed region. The residues Asp153
(E), Asp153(I), and Asp153(N) of the Fab fragments are found in the disallowed
region of the Ramachandran plot. Data collection and model statistics are shown in
Supplementary Table 4. The atomic coordinates and structure factors have been
deposited in the Protein Data Bank, www.pdb.org (PDB-ID code 6ERX). Buried
surface areas were calculated with AreaIMol53. Images were generated with the
PyMOL Molecular Graphics System, Schrödinger, LLC.
Electron microscopy data acquisition and image processing. Negatively stained
specimens were prepared following an established protocol with minor modiﬁca-
tions54. Speciﬁcally, 2.5 µl of sample was applied to glow-discharged copper elec-
tron microscopy (EM) grids covered with a thin layer of continuous carbon ﬁlm,
and the grids were stained with 2% (w/v) uranyl formate. The sample concentra-
tions of BAFF 60-mer, BAFF 60-mer bound with atacicept, and BAFF 3-mer bound
with Fab were 23, 20, and 8.8 μg/ml, respectively. These grids were imaged on a
Tecnai T12 electron microscope (FEI) operated at 120 kV at a nominal magniﬁ-
cation of 67,000× using a 4k × 4k CCD camera (UltraScan 4000, Gatan), corre-
sponding to a calibrated pixel size of 1.68 Å on the specimen level.
The EM data were processed using SAMUEL and SamViewer55. Negative-stain
EM images were binned over 2 × 2 pixels for further processing, yielding a pixel
size of 3.36 Å. Particle picking was performed using a semi-automated procedure56.
2D classiﬁcation of selected particle images was carried out with 'samclasscas.py',
which uses SPIDER operations to run 10 cycles of correspondence analysis,
K-means classiﬁcation, and multi-reference alignment57.
Statistics. Group sizes for animal experiments were chosen to detect 40% differ-
ences between conditions, with variation coefﬁcients of 15–20% (4 animals/group).
Animals were assigned randomly to groups, except for males and females that were
distributed equally between groups. Analyses were not blinded. Normal distribu-
tion of data was conﬁrmed by normality tests using Prism (D’Agostino and
Pearson test for n ≥ 8, Kolmogorov–Smirnov test for n= 6 or 7), or was assumed
for smaller size groups. One-way analysis of variance with Bonferroni’s multiple
comparison tests was used to compare selected groups using Prism. One-way
analysis of variance assumes that the standard deviation of the different groups is
equal, an assumption that was not always met according to Bartlett’s test for
equality of variance. But as this assumption is of little importance when group sizes
are (almost) equal, this was ignored.
Data availability. The authors declare that the data supporting the ﬁndings of this
study are available within the article, in its supplementary information ﬁles, as a
dataset58, or are available upon reasonable requests to the authors. The structural
datasets are available in the Protein Data Bank repository, www.pdb.org, under the
PDB-ID code 6ERX.
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SUPPLEMENTARY INFORMATION 
A loop region of BAFF controls B cell survival and regulates recognition by 
different inhibitors.      
Vigolo et al. 
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Supplementary Figure 1 (related to Figure 1). Mutations in the flap do not affect binding of BAFF 
to BAFFR and TACI on BJAB cells. 
A. Titrated amounts of Flag-tagged human BAFF 3-mers (WT or with flap mutations) were added to
BJAB cells, and binding was revealed with an anti-FLAG antibody. Binding of BAFF to BJAB BAFFR-
CRISPR/Cas9-ko (Ø BAFFR) cells was also measured at the highest BAFF concentration.
B. Same as panel A, using BJAB Ø BAFFR cells expressing human TACI.
C. Same as panel A, but titrating FLAG-tagged mouse BAFF 3-mers.
D. Same as panel B, but titrating FLAG-tagged mouse BAFF 3-mers.
For panels A-D, each point shows the mean ± SEM of technical triplicates. Experiments of panels A-D
were performed twice. MFI: mean fluorescence intensity.
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Supplementary Figure 2 (related to Figure 3). Generation of Baff E247K knock-in mice. 
A. Schematic representation of the relevant sequence of the mouse Baff gene in wild type genome (WT),
in recombined knock-in embryonic stem cells (ES) and in knock-in mice (KI) after deletion of the
neomycin resistance (NeoR) cassette. Location of Baff exons 5, 6 and 7 are indicated as bold black lines.
Positions of the PCR fragment amplified for screening recombined ES cells (see panel B) and of the 5’
probe for southern blot (of panel C) are indicated as purple lines. Restriction sites of interest are also
shown.
B. Identification of recombined clones of ES cells, including clone 3H5 that was selected for generating
knock-in mice. Size markers (in base pairs) are shown on the left. This experiment was performed once.
C. Southern blot of HindIII-digested ES cell genomic DNA revealed with a 5’ probe (top) and with a
NeoR probe (bottom). This experiment was performed once.
D. Example of genotyping result for knock-in (ki/ki), heterozygous (ki/wt) and wild type (wt/wt) mice.
Experiment performed once in this format (> 5 times in similar formats).
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Supplemental Figure 3 (related to figures 3, 4, 5 and supplementary figure 1). Gating strategy for 
the identification of B cell subsets. 
A. Gating strategy to identify B cells subsets in the spleen, for data shown in Fig. 3C-H, Fig. 5 and
supplementary tables 1-3. SSC: side scatter. FSC: forward scatter. -W: width. -H: height. -A: area.  
B. Same as panel A, but for lymph node cells.
C. Gating strategy used for supplementary figure 1.
D. Gating strategy for Fig. 4F. CFSE: carboxyfluorescein succinimidyl ester.
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Supplementary Figure 4 (related to Figure 3). Detection of recombinant FLAG-mBAFF by 
AlphaLISA. 
A. Detection by AlphaLISA of total FLAG-mBAFF (WT or E247K) at the indicated concentrations using
5A8-coupled acceptor beads and biotinylated Sandy-2.
B. Schematic representation of the assay used in panel A.
C. Detection by AlphaLISA of receptor binding-competent FLAG-mBAFF (WT or E247K) at the
indicated concentrations using TACI-Fc-coupled acceptor beads and biotinylated Sandy-2. This
experiment was performed twice.
D. Schematic representation of the assay used in panel C.
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Supplementary Figure 5 (related to Figure 6). Belimumab does not bind to BAFF 60-mer. 
Belimumab was incubated for 3 days with a 100-fold mass excess of BAFF 60-mer. The mixture was then 
size-fractionated by gel filtration chromatography. Belimumab was detected by Western blot in the eluted 
fractions, while the more abundant BAFF 60-mer was visualized by Ponceau staining of the membrane. 
Ribonuclease A (Rib A) was added in samples as an internal standard just before injection on the column. 
A. Elution profile of molecular weight standards measured by absorbance at 280 nm. mAU: milli
absorbance units.
B, C. 200 µg of un-complexed belimumab was detected by its absorbance at 280 nm, or by western
blotting of eluted fractions. HC: heavy chain.
D. 2 µg of un-complexed belimumab was detected by western blotting of eluted fractions.
E, F. Elution profile of 2 µg of belimumab incubated with 200 µg of BAFF 60-mer. Belimumab was
detected by western blotting (E) and BAFF 60-mer by Ponceau staining. Note that BAFF was 60-mer
during the gel filtration, but dissociated into its 18.4 kDa monomeric constituents during the SDS-PAGE
procedure. This experiment was performed once.
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Supplementary Figure 6 (related to Figure 8). Mutation H218A in the flap of BAFF does not grossly 
alter the affinity for belimumab. 
The fusion proteins Fc-BAFF, with or without the point mutation H218A in the flap of BAFF, were 
expressed in HEK 293T cells by transient transfection, then affinity purified on immobilized TACI-Fc. 
Fusion of a Fc moiety at the N-terminus of BAFF has at least two consequences: i) BAFF cannot form 60-
mers for steric hindrance reasons and thus is recognized by belimumab (see Fig. 6A) and ii) fusion of a 
dimeric Fc to a trimeric ligand leads to the formation of active hexamers with two trimeric ligands 
intrinsically cross-linked by three dimeric Fc 1. Fc-BAFF should thus be active regardless of mutations in 
the flap, and the flap should be accessible to belimumab. 
A.- Coomassie blue staining of 10 µg of Fc-BAFF WT and Fc-BAFF H218A produced by transient 
transfection in HEK 293T cells and affinity purification on immobilized TACI-Fc. 
B.- Fc-BAFF WT and H218A were incubated at the indicated concentrations for 16 h with BAFFR:Fas 
reporter cells, after which time cell viability was measured with the PMS/MTS cell viability assay. The 
experiment was performed twice. 
C.- Fc-BAFF WT or Fc-BAFF H218A were coated in an ELISA plate. The biotinylated Fab fragment of 
belimumab was added at various dilutions, and binding to the coated Fc-ligand was detected with 
peroxidase-coupled streptavidin. The arrow indicates the concentration chosen for subsequent competition 
assays (see panels D and E). Mean ± SEM of duplicates. 
D.- Fc-BAFF WT was coated in an ELISA plate. After the blocking step, soluble Fc-BAFF WT or H218A 
was added in wells at twice the indicated final concentrations. Without wash, biotinylated belimumab Fab 
was subsequently added and mixed immediately to reach a fixed final concentration of 50 ng/ml. After 
incubation and a washing step, bound Fab was detected as described in panel C. Mean ± SEM of 
duplicates. 
E.- Same as panel D, except that Fc-BAFF H218A was coated in the ELISA plate. Mean ± SEM of 
duplicates. The experiments in panels C-E were performed twice.  
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Supplementary Figure 7 (related to Figure 8). Stereo image of a portion of the electron density map 
of the BAFF – belimumab complex. 
Stereo image showing a portion of the BAFF (yellow) - belimumab (green) complex around the flap loop 
of BAFF. The 2Fo-Fc electron density map contoured at 1 σ is shown as a blue mesh.  
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Supplementary Figure 8 (related to Figure 8). Interface of belimumab bound to BAFF. 
A. Residues at the interface of the interaction between BAFF and belimumab that are closer than 4 Å are
connected by black lines. CDR: complementarity-determining regions. DXL: Asp-Xxx-Leu motif. The
DXL motif is at the centre of the binding of BAFF with its receptors (Fig. 8B, E).
B. Detailed view of the interaction site between belimumab and BAFF. Most residues at the contact site
are identified. Mutation H218A (His218  A218) that prevents assembly of BAFF 3-mer into 60-mers is
also shown (but is not part of the BAFF-belimumab contact site).
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Supplementary Figure 9 (related to Fig. 2B, 2C, 3A, 3B and supplementary Fig. 5C, D, E, F). Uncropped WB (and Ponceau) images. 
HC: heavy chain. LC: Light chain. 
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Supplementary Table 1 (related to Figure 3E, F). Lymphocytes counts in BAFF E247K knock-in mice and wild-type littermates compared to 
BAFF-deficient mice. 
Cell number (millions) Cell frequency (%) 
BAFF genotype + / + E247K / + E247K / 
E247K 
− / − + / + E247K / + E247K / 
E247K 
− / − 
n a 
Spleen 
4 3 3 3
All cells 42.9 ± 3.4 b 32.9 ± 4.0 29.0 ± 1.4 16.3 ± 1.1 100 100 100 100 
T cells c 11.3 ± 0.7 10.5 ± 2.0 11.9 ± 1.8 9.22 ± 0.02 26.7 ± 2.1 31.2 ± 2.2 40.5 ± 4.2 57.2 ± 3.7 
B cells d 25.7 ± 2.2 17.4 ± 2.1 8.7 ± 1.1 3.8 ± 0.7 59.8 ± 1.3 53.0 ± 2.2 29.7 ± 2.3 23.1 ± 2.3 
Immature e 4.3 ± 0.3 4.5 ± 0.3 4.5 ± 1.1 2.1 ± 0.6 10.4 ± 1.4 14.0 ± 1.2 15.2 ± 3.0 12.4 ± 1.5 
Mature f 20.3 ± 2.2 12.6 ± 1.9 4.2 ± 0.1 1.7 ± 0.1 46.9 ± 2.2 38.1 ± 2.6 14.5 ± 0.8 10.4 ± 0.7 
MZ g 0.93 ± 0.20 0.32 ± 0.09 0.053 ± 0.008 0.048 ± 
0.005 
2.1 ± 0.3 0.96 ± 0.18 0.18 ± 0.03 0.29 ± 0.01 
Lymph nodes h 
All cells ND ND ND ND 100 100 100 100 
T cells ND ND ND ND 76.2 ± 1.9 83.6 ± 0.5 95.2 ± 0.4 96.9 ± 0.2 
B cells ND ND ND ND 21.8 ± 1.6 14.6 ± 0.7 3.9 ± 0.4 1.2 ± 0.2 
Ratio
B/T ratio 0.29 ± 0.03 0.18 ± 0.01 0.031 ± 0.005 0.013 ± 
0.003 
a) 8 to 12 weeks-old, randomized gender. b) mean ± SEM. c) CD3+, CD19−. d) CD19+, CD3−. e) CD19+, CD93+, CD1dlow. f) CD19+, CD93−,
CD1d−. g) CD19+, CD93−, CD1dhigh. h) pooled inguinal, axillary and brachial lymph nodes.
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Supplementary Table 2 (related to Figure 3G, H). Lymphocytes counts in BAFF E247K mutant heterozygous mice compared to wild-type 
heterozygous littermates. 
Cell number (millions) Cell frequency (%) 
BAFF genotype + / + + / − E247K / + E247K / − + / + + / − E247K / + E247K / − 
n a 
Spleen 
3 5 4 4 
All cells 68.40 ± 2.84 33.71 ± 3.53 39.01 ± 6.65 24.97 ± 1.15 100 100 100 100 
T cells c 29.23 ± 2.83 18.57 ± 1.73 24.79 ± 5.46 19.77 ± 0.83 42.57 ± 2.53 55.80 ± 2.78 61.95 ± 3.18 79.30 ± 1.32 
B cells d 36.58 ± 1.41 12.14 ± 1.86 12.01 ± 1.13 3.54 ± 0.37 53.7 ± 3.16 35.02 ± 2.90 32.08 ± 2.73 14.10 ± 1.12 
Immature e 3.78 ± 0.97 2.30 ± 0.61 1.91 ± 0.64 1.66 ± 0.29 5.55 ± 1.40 6.44 ± 1.29 4.47 ± 085 6.55 ± 0.97 
T1 f 2.36 ± 0.73 1.60 ± 0.47 1.31 ± 0.50 1.33 ± 0.25 3.46 ± 1.05 4.50 ± 1.02 2.98 ± 0.74 5.22 ± 0.84 
T2 g 1.34 ± 0.22 0.63 ± 0.14 0.56 ± 0.14 0.31 ± 0.04 1.96 ± 0.32 1.77 ± 0.27 1.39 ± 0.15 1.23 ± 0.11 
Mature h 31.33 ± 0.75 9.50 ± 1.40 9.73 ± 0.47 1.87 ± 0.11 46.02 ± 2.68 27.61 ± 2.39 26.63 ± 3.39 7.28 ± 0.44 
MZ i 0.528 ± 0.105 0.119 ± 0.024 0.136 ± 0.033 0.013 ± 0.001 0.765 ± 0.125 0.337 ± 0.060 0.358 ± 0.108 0.051 ± 0.005 
Lymph node j
All cells 7.92 ± 0.91 6.00 ± 0.37 5.60 ± 0.73 6.68 ± 1.07 100 100 100 100 
T cells 5.89 ± 0.91 5.14 ± 0.33 4.70 ± 0.65 6.30 ± 0.97 73.70 ± 2.76 85.74 ± 1.77 83.60 ± 1.71 94.55 ± 1.05 
B cells 1.71 ± 0.07 0.56 ± 0.12 0.58 ± 0.04 0.09 ± 0.02 22.20 ± 2.82 9.26 ± 1.82 10.81 ± 1.47 1.29 ± 0.19 
Ratio 
B/T ratio  0.305 ± 0.048 0.110 ± 0.024 0.130 ± 0.019 0.014 ± 0.002 
a) 8 to 12 weeks-old, randomized gender. b) mean ± SEM. c) CD3+CD19−. d) CD19+CD3−. e) CD19+CD93+CD1dlow. f)
CD19+CD93+CD1dlowIgMhighIgDlow. g) CD19+CD93+CD1dlowIgMlowIgDhigh. h) CD19+CD93−CD1d−. i) CD19+CD93−CD1dhigh. j) pooled inguinal,
axillary and brachial lymph nodes.
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Supplementary Table 3 (related to Figure 5). Lymphocytes in BAFF E247K mice treated with anti-BAFF crosslinking antibodies compared to 
wild-type and BAFF-/- mice. 
Cell number (millions) Cell frequency (%) 
BAFF 
genotype E247K / E247K − / − + / + E247K / E247K − / − + / +
Treatment EctoD1 (ctrl) Sandy5 5A8 − − EctoD1 (ctrl) Sandy5 5A8 − − 
n a 
Spleen 
6 6 6 5 6
All cells 13.82 ± 1.73 22.13 ± 4.12 22.99 ± 2.39 21.03 ± 1.63 33.01 ± 4.90 100 100 100 100 100
T cells c 10.35 ± 1.39 12.33 ± 2.09 12.14 ± 1.16 14.97 ± 1.27 15.04 ± 2.27 74.58 ± 1.71 57.17 ± 2.72 53.12 ± 0.97 71.22 ± 3.77 45.88 ± 2.82 
B cells d 2.11 ± 0.39 8.30 ± 1.96 9.33 ± 1.17 1.46 ± 0.10 14.49 ± 1.93 15.22 ± 1.72 35.52 ± 3.11 40.17 ± 1.63 6.99 ± 0.16 44.70 ± 1.65 
Immature e 1.42 ± 0.29 2.79 ± 0.66 2.82 ± 0.51 0.95 ± 0.07 3.69 ± 0.33 10.33 ± 1.59 11.98 ± 1.16 11.90 ± 1.36 4.54 ± 0.23 11.98 ± 1.41 
T1 f 0.62 ± 0.13 0.99 ± 0.26 0.92 ± 0.16 0.53 ± 0.04 1.10 ± 0.09 4.59 ± 0.85 4.12 ± 0.67 3.85 ± 0.40 2.52 ± 0.12 3.60 ± 0.52 
T2 g 0.70 ± 0.15 1.56 ± 0.35 1.74 ± 0.33 0.33 ± 0.03 2.28 ± 0.23 4.98 ± 0.65 6.83 ± 0.33 7.31 ± 0.90 1.58 ± 0.09 7.36 ± 0.79 
Mature h 0.65 ± 0.11 5.32 ± 1.26 6.26 ± 0.75 0.48 ± 0.04 10.06 ± 1.64 4.64 ± 0.36 22.72 ± 1.94 27.23 ± 1.44 2.27 ± 0.12 30.49 ± 1.53 
MZ i 0.005 ± 0.001 0.092 ± 0.025 0.127 ± 0.023 0.012 ± 0.002 0.521 ± 0.086 0.038 ± 0.005 
0.381 ± 
0.052 
0.545 ± 
0.076 
0.058 ± 
0.004 
1.552 ± 
0.084 
LN j 
All cells ND ND ND ND ND 100 100 100 100 100
T cells ND ND ND ND ND 94.38 ± 0.98 87.33 ± 0.35 83.13 ± 1.23 96.04 ± 0.77 77.73 ± 3.19 
B cells ND ND ND ND ND 3.67 ± 1.68 10.85 ± 0.35 15.35 ± 1.16 1.12 ± 0.13 20.22 ± 2.88 
Ratio
B/T ratio 0.039 ± 
0.008 
0.124 ± 
0.004 
0.186 ± 
0.018 
0.012 ± 
0.001 
0.271 ± 
0.053 
a) 8 to 12 weeks-old, randomized gender. b) mean ± SEM. c) CD3+CD19−. D) CD19+CD3−. E) CD19+CD93+CD1dlow. F)
CD19+CD93+CD1dlowIgMhighIgDlow. G) CD19+CD93+CD1dlowIgMlowIgDhigh. H) CD19+CD93−CD1d−. i) CD19+CD93−CD1dhigh. J) pooled
inguinal, axillary and brachial lymph nodes.
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Supplementary Table 4 (related to Figures 7J-K and 8). Data collection and refinement statistics. 
BAFF-Belimumab Fab
Data collection 
Space group P21 
Cell dimensions 
   a, b, c (Å) 135.69, 135.50, 138.18 
   a, b, g (°) 90.0, 91.9, 90.0 
Resolution (Å) 2.90 (3.15-2.90) a 
Rsym or Rmerge 11.9 (57.6)
I / sI 11.24  (3.05) 
Completeness (%) 98.7 (95.4) 
Redundancy 3.36 (3.21)
Refinement 
Resolution (Å) 138.11-2.90 
No. reflections 108711(654)b 
Rwork / Rfree 0.193 / 0.23.2 
No. atoms 
    Protein 25957 
    Water 273 
B-factors
Protein 58.31
    Water 34.17 
R.m.s. deviations
Bond lengths (Å) 0.010 
Bond angles (°) 1.540 
a Values in parentheses are for highest-resolution shell. 
b Randomly selected test set 0.6% of data 
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Supplementary Table 5. Plasmids used in this study. 
Plasmid Designation Protein encoded Vector 
ps336 FLAG-hBAFF HA signal-FLAG-GPGQVQLQ-hBAFF (aa 137-285) PCR3
ps657 FLAG-mBAFF HA signal-FLAG-GPGQVQLQVD-mBAFF (aa 127-309) PCR3 
ps739 hBCMA-Fc Ig signal-EVKLVPRGS-hBCMA (aa 2-54)-VD-hIgG1 (aa 245-470) PCR3
ps837 mBCMA-Fc Ig signal-DVT-mBCMA (aa 1-46)-VD-hIgG1 (aa 245-470) PCR3
ps1111 mTACI-Fc HA signal-LE-mTACI (aa 2-78)-AAAVD-hIgG1 (aa 245-470) PCR3 
ps1377 pMSCS-puro Modified pMSCV-puro (Clontech) with HindIII-BglII-EcoRI-NotI-XhoI-HpaI-ApaI sites ps1377 
ps1196 Fc-PS-hBAFF HA signal LD h Fc (h IgG1 aa245-470) RSPQPQPKPQPKPEPEGS-PreSci-GSL h BAFF 
(aa136-285) 
PCR3 
ps1910 mBAFF mBAFF (aa 1-309) PCR3 
ps2297 mBAFFR-Fc HA signal-LD-mBAFFR (aa 2-70)-VD- hIgG1 (aa 245-470) PCR3 
ps2308 hBAFFR:Fas HA signal-LE-hBAFFR (aa 2-71)-EFGSVD-hFas (aa 169-355) ps1377 
ps2355 mBAFF H242A mBAFF (aa 1-309, H242A) PCR3 
ps2394 hBAFF H218A hBAFF (aa 1-285, H218A) PCR3 
ps2565 His-hBAFF MRGSHHHHHHGS-h BAFF (aa134-285) PCR3
ps2566 His-hBAFF H218A MRGSHHHHHHGS-h BAFF H218A (aa134-285) PCR3 
ps2583 mBAFF E247K mBAFF (aa 1-309, E247K) PCR3
ps2784 hBAFF hBAFF (aa 1-285) PCR3 
ps2825 Fc-hBAFF HA signal LD h Fc (h IgG1 aa245-470) RSPQPQPKPQPKPEPEGSL h BAFF (aa136-285) PCR3 
ps2846 mBAFF E247K ki Vector for generation of BAFF E247K knock-in mice pBluescript 
ps2859 mBAFF 5’probe Vector containing the 5’ Southern blot probe (of Suppl Fig. 2) as HindIII/BamHI fragment pBluescript 
ps3195 FLAG-hBAFF H218A HA signal-FLAG-GPGQVQLQ-hBAFF (aa 137-285, H218A) PCR3
ps3196 hBAFF E223K hBAFF (aa 1-285, E223K) PCR3
ps3198 FLAG-hBAFF E223K HA signal-FLAG-GPGQVQLQ-hBAFF (aa 137-285, E223K) PCR3 
ps3199 FLAG-mBAFF E247K HA signal-FLAG-GPGQVQLQVD-mBAFF (aa 127-309, E247K) PCR3
ps3201 FLAG-mBAFF H242A HA signal-FLAG-GPGQVQLQVD-mBAFF (aa 127-309, H242A) PCR3 
ps3286 hTACI hTACI full (aa 1-293) ps1377 
ps3344 psPAX2 Addgene #12260 ps3344 
ps3345 pCMV-VSV-g Addgene #8454 ps3345 
ps3391 Lenticrispr v2 Addgene #52961 ps3391 
ps3417 gRNA hBAFFR for 
CRISP/Cas9 
5’CACCGGGCCGAGTGCTTCGACCTGC-3’ and 5’-TTTGCGTCCAGCTTCGTGAG 
CCGGG-3’ annealed and cloned into BsmB1 sites of ps3391 
ps3391 
ps3784 Fc-PS-hBAFF H218A HA signal LD h Fc (h IgG1 aa245-470) RSPQPQPKPQPKPEPEGS-PreSci-GSL h BAFF 
(aa136-285, H218A) 
PCR3 
    FLAG = DYKDDDDK    HA signal=MAIIYLILLFTAVRG    Ig signal=MNFGFSLIFLVLVLKG           PreSci= LEVLFGGP 
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